Given that no difference in AML clinical outcomes between lower mutation allele and R882 wild type patients was observed in the study, the inconsistency probably stems from lack of consideration of allele ratio of DNMT3A R882 mutations in those studies. This evidence concerns the gene DNMT3A and acute myeloid leukemia.